Satellos Bioscience Inc. SEC Filings

Satellos Bioscience Inc. is calling a virtual-only annual general meeting of shareholders on June 17, 2026 at 1:00 p.m. Toronto time to review 2025 financial statements, elect directors and appoint auditors. Only shareholders of record as of May 12, 2026 may vote.

The circular explains detailed proxy and voting procedures for registered and non-registered shareholders, including the need for control numbers and invite codes to vote online. Management recommends voting in favour of all resolutions, including the reappointment of PricewaterhouseCoopers LLP as auditor.

The filing also outlines 2025 compensation for key executives and directors, stock option and RSU awards, and the structure of Satellos’ Equity Incentive Plan. That plan can cover up to 3,124,679 shares, with 2,766,563 awards outstanding and a 2025 burn rate of 7.9% of outstanding shares.

Satellos Bioscience Inc. ownership disclosure: three reporting persons state combined beneficial ownership of 1,137,041 ordinary shares, representing 7.35% of the class.

The filing attributes the 7.35% figure to a calculation using 15,458,903 ordinary shares outstanding as of February 5, 2026 and 3,641 common shares issuable upon exercise of options owned by the reporting persons. Ownership breaks down into 126,874 shares with sole voting/dispositive power and 1,010,167 shares with shared voting/dispositive power, held across individuals and affiliated entities named in the filing.

Satellos Bioscience Inc. ownership disclosure: three reporting persons state combined beneficial ownership of 1,137,041 ordinary shares, representing 7.35% of the class.

The filing attributes the 7.35% figure to a calculation using 15,458,903 ordinary shares outstanding as of February 5, 2026 and 3,641 common shares issuable upon exercise of options owned by the reporting persons. Ownership breaks down into 126,874 shares with sole voting/dispositive power and 1,010,167 shares with shared voting/dispositive power, held across individuals and affiliated entities named in the filing.

Satellos Bioscience Inc. reported a wider net loss of $9,768 for the three months ended March 31, 2026, compared with $6,141 a year earlier, as it ramped spending on clinical programs for its lead DMD candidate SAT-3247. Research and development expenses rose to $7,310 from $4,542, driven mainly by the BASECAMP and TRAILHEAD Phase 2 studies and related manufacturing work, while general and administrative costs increased to $2,733 from $1,937 due to higher professional and operating expenses tied to its Nasdaq listing and growth. A February 2026 equity offering of 5,168,019 Common Shares and 495,049 pre-funded warrants generated net proceeds of $51,901, lifting cash and short-term investments to $69,911 at March 31, 2026 from $27,710 at year-end and supporting management’s view that available cash provides runway through 2027. BASECAMP, a 51-patient pediatric Phase 2 trial, is enrolling across 11 active sites and remains on track to complete enrollment in Q3 2026, while the adult TRAILHEAD Phase 2 study has been initiated in the United States, with participants from the earlier Phase 1b trial already re-started on SAT-3247.

Satellos Bioscience Inc. reported a wider net loss of $9,768 for the three months ended March 31, 2026, compared with $6,141 a year earlier, as it ramped spending on clinical programs for its lead DMD candidate SAT-3247. Research and development expenses rose to $7,310 from $4,542, driven mainly by the BASECAMP and TRAILHEAD Phase 2 studies and related manufacturing work, while general and administrative costs increased to $2,733 from $1,937 due to higher professional and operating expenses tied to its Nasdaq listing and growth. A February 2026 equity offering of 5,168,019 Common Shares and 495,049 pre-funded warrants generated net proceeds of $51,901, lifting cash and short-term investments to $69,911 at March 31, 2026 from $27,710 at year-end and supporting management’s view that available cash provides runway through 2027. BASECAMP, a 51-patient pediatric Phase 2 trial, is enrolling across 11 active sites and remains on track to complete enrollment in Q3 2026, while the adult TRAILHEAD Phase 2 study has been initiated in the United States, with participants from the earlier Phase 1b trial already re-started on SAT-3247.

Satellos Bioscience Inc., a clinical-stage biotechnology company focused on degenerative muscle diseases, will present at the Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21-22, 2026. Co-founder and CEO Frank Gleeson will give a presentation on April 21 at 11:30 a.m., with a live webcast and replay available via the Investors section of the company’s website.

The company is developing SAT-3247, an orally administered small molecule therapy aimed at restoring muscle repair and regeneration. SAT-3247 is being studied as a potential disease-modifying treatment for Duchenne muscular dystrophy in two Phase II trials, BASECAMP in pediatric patients and TRAILHEAD in adults.

Satellos Bioscience Inc., a clinical-stage biotechnology company focused on degenerative muscle diseases, will present at the Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21-22, 2026. Co-founder and CEO Frank Gleeson will give a presentation on April 21 at 11:30 a.m., with a live webcast and replay available via the Investors section of the company’s website.

The company is developing SAT-3247, an orally administered small molecule therapy aimed at restoring muscle repair and regeneration. SAT-3247 is being studied as a potential disease-modifying treatment for Duchenne muscular dystrophy in two Phase II trials, BASECAMP in pediatric patients and TRAILHEAD in adults.

Satellos Bioscience Inc. filed its Annual Report on Form 40-F disclosing incorporated exhibits including an Annual Information Form, audited consolidated financial statements for the years ended December 31, 2025 and 2024, and an MD&A.

The filing names PricewaterhouseCoopers LLP as auditor and states the company is an emerging growth company. Shares outstanding were 15,458,903 Common Shares as of the close of the period covered by the annual report. The filing includes SOX certifications and references disclosure controls and internal control information in the MD&A.

Satellos Bioscience Inc. filed its Annual Report on Form 40-F disclosing incorporated exhibits including an Annual Information Form, audited consolidated financial statements for the years ended December 31, 2025 and 2024, and an MD&A.

The filing names PricewaterhouseCoopers LLP as auditor and states the company is an emerging growth company. Shares outstanding were 15,458,903 Common Shares as of the close of the period covered by the annual report. The filing includes SOX certifications and references disclosure controls and internal control information in the MD&A.

Satellos Bioscience reported a 2025 net loss of $24.9 million, up from $20.6 million in 2024, as it increased investment in its lead Duchenne muscular dystrophy drug, SAT-3247. R&D expenses rose to $18.4 million and G&A to $8.0 million.

The company ended 2025 with $27.7 million in cash, cash equivalents and short-term investments and subsequently raised $57.2 million in an equity offering. Management expects this to fund operations through 2027, supporting two Phase 2 SAT-3247 trials in Duchenne.

Satellos initiated BASECAMP, a global, placebo-controlled pediatric Phase 2 trial, and expanded TRAILHEAD, an adult Phase 2 study, where early functional data showed maintained or improved grip strength over roughly 9–13 months of aggregate treatment. New preclinical data in FSHD suggest potential use of SAT-3247 beyond Duchenne.

Satellos Bioscience Inc. reported interim clinical and biomarker results for its oral drug candidate SAT-3247 in Duchenne muscular dystrophy at the 2026 MDA Clinical & Scientific Conference.

In the ongoing Phase 2 TRAILHEAD study in adults with Duchenne, investigators observed continued improvement in handgrip strength and overall stability of elbow and shoulder strength at Day 56 after re-enrollment, with greater strength gains in participants who started with more muscle mass.

A 28-day Phase 1a/b study (CL-101) showed consistent changes across more than 11,000 serum proteins, including reductions in established Duchenne biomarkers within two weeks of SAT-3247 treatment. Satellos also highlighted development of a regenerative index tool now used in the pediatric BASECAMP trial and preclinical data in a mouse model of facioscapulohumeral muscular dystrophy, where 12-week dosing significantly enhanced muscle strength, suggesting broader potential beyond Duchenne.

Satellos Bioscience Inc. reported interim clinical and biomarker results for its oral drug candidate SAT-3247 in Duchenne muscular dystrophy at the 2026 MDA Clinical & Scientific Conference.

In the ongoing Phase 2 TRAILHEAD study in adults with Duchenne, investigators observed continued improvement in handgrip strength and overall stability of elbow and shoulder strength at Day 56 after re-enrollment, with greater strength gains in participants who started with more muscle mass.

A 28-day Phase 1a/b study (CL-101) showed consistent changes across more than 11,000 serum proteins, including reductions in established Duchenne biomarkers within two weeks of SAT-3247 treatment. Satellos also highlighted development of a regenerative index tool now used in the pediatric BASECAMP trial and preclinical data in a mouse model of facioscapulohumeral muscular dystrophy, where 12-week dosing significantly enhanced muscle strength, suggesting broader potential beyond Duchenne.

Satellos Bioscience Inc. is highlighting progress in its lead drug candidate SAT-3247 through two oral presentations and three posters at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference in Orlando from March 8–11. The talks will cover data from a completed Phase 1a/b study of SAT-3247 in healthy volunteers and adults with Duchenne muscular dystrophy, plus new preclinical data in a mouse model of facioscapulohumeral muscular dystrophy. SAT-3247 is an oral small molecule that targets AAK1, aiming to restore muscle stem cell signaling and promote muscle regeneration as a potential disease-modifying treatment for DMD and other degenerative muscle conditions.

Satellos Bioscience Inc. is highlighting progress in its lead drug candidate SAT-3247 through two oral presentations and three posters at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference in Orlando from March 8–11. The talks will cover data from a completed Phase 1a/b study of SAT-3247 in healthy volunteers and adults with Duchenne muscular dystrophy, plus new preclinical data in a mouse model of facioscapulohumeral muscular dystrophy. SAT-3247 is an oral small molecule that targets AAK1, aiming to restore muscle stem cell signaling and promote muscle regeneration as a potential disease-modifying treatment for DMD and other degenerative muscle conditions.

Satellos Bioscience Inc., a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, will present at several upcoming investor conferences. Management is scheduled to participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, the TD Cowen 46th Annual Health Care Conference, and the Leerink Partners Global Healthcare Conference, through presentations and investor meetings. Live webcasts of the presentations will be accessible on the company’s website in the Investors section. The company highlights its lead oral small molecule candidate SAT-3247, which targets AAK1 and is being developed as a potential disease-modifying treatment for Duchenne muscular dystrophy, supported by ongoing Phase 2 studies in adult and pediatric participants.

Satellos Bioscience Inc., a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, will present at several upcoming investor conferences. Management is scheduled to participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, the TD Cowen 46th Annual Health Care Conference, and the Leerink Partners Global Healthcare Conference, through presentations and investor meetings. Live webcasts of the presentations will be accessible on the company’s website in the Investors section. The company highlights its lead oral small molecule candidate SAT-3247, which targets AAK1 and is being developed as a potential disease-modifying treatment for Duchenne muscular dystrophy, supported by ongoing Phase 2 studies in adult and pediatric participants.

Satellos Bioscience Inc. is organizing a virtual key opinion leader event on February 24, 2026 at 3:30 p.m. ET to discuss its lead drug candidate SAT-3247 for Duchenne muscular dystrophy (DMD). Neuromuscular disease expert Dr. Kevin M. Flanigan will review the unmet need and current DMD treatment landscape alongside company management.

The event will cover SAT-3247’s mechanism as an oral small molecule targeting AAK1 to help restore muscle stem-cell signaling disrupted by loss of dystrophin in DMD. It will highlight results from a completed Phase 1a/b trial in healthy volunteers and adults with DMD and provide updates on ongoing Phase 2 studies, including the adult open-label TRAILHEAD study and the global randomized, placebo-controlled pediatric BASECAMP trial.

Satellos Bioscience Inc. is organizing a virtual key opinion leader event on February 24, 2026 at 3:30 p.m. ET to discuss its lead drug candidate SAT-3247 for Duchenne muscular dystrophy (DMD). Neuromuscular disease expert Dr. Kevin M. Flanigan will review the unmet need and current DMD treatment landscape alongside company management.

The event will cover SAT-3247’s mechanism as an oral small molecule targeting AAK1 to help restore muscle stem-cell signaling disrupted by loss of dystrophin in DMD. It will highlight results from a completed Phase 1a/b trial in healthy volunteers and adults with DMD and provide updates on ongoing Phase 2 studies, including the adult open-label TRAILHEAD study and the global randomized, placebo-controlled pediatric BASECAMP trial.